| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0000100 | Exon-Exon | chr6:4706393-4892613 | chr6:4706159-4892379 | 984 nt | 0.5325 |
| hsa_CDYL_0000300 | Exon-Exon | chr6:4715975-4892613 | chr6:4715741-4892379 | 891 nt | 0.5387 |
| hsa_CDYL_0001000 | Exon-Exon | chr6:4836332-4892613 | chr6:4836098-4892379 | 878 nt | 0.5262 |
| hsa_CDYL_0004300 | Exon-Exon | chr6:4890226-4892613 | chr6:4889992-4892379 | 802 nt | 0.5349 |
| hsa_CDYL_0005200 | Exon-Exon | chr6:4891947-4892613 | chr6:4891713-4892379 | 667 nt | 0.5412 |
| hsa_CDYL_0005300 | Exon-Exon | chr6:4891947-4936005 | chr6:4891713-4935771 | 924 nt | 0.5152 |
| hsa_CDYL_0005400 | Exon-Exon | chr6:4891947-4937919 | chr6:4891713-4937685 | 1045 nt | 0.5148 |
| hsa_CDYL_0005500 | Exon-Exon | chr6:4891947-4937971 | chr6:4891713-4937737 | 1097 nt | 0.5105 |
| hsa_CDYL_0009600 | Exon-Exon | chr6:4935749-4937971 | chr6:4935515-4937737 | 430 nt | 0.4628 |
| hsa_CDYL_0010600 | Exon-Exon | chr6:4954132-4955778 | chr6:4953898-4955544 | 1647 nt | 0.3843 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].